

Intellipharmaeutics International Inc.  
Form 6-K  
October 15, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

**For the month of October 2014.**

Commission File Number: **000-53805**

**Intellipharmaeutics International Inc.**

(Translation of registrant's name into English)

**30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F [ x ] Form 40-F [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Edgar Filing: Intellipharmaeutics International Inc. - Form 6-K

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

This Report of Foreign Private Issuer on Form 6-K and the attached exhibits 99.1 and 99.2 shall be incorporated by reference into the Company's effective Registration Statements on Form F-3, as amended and supplemented (Registration Statement Nos. 333-172796, 333-178190 and 333-196112), filed with the Securities and Exchange Commission, from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished by Intellipharmaeutics International Inc. under the Securities Act of 1933 or the Securities Exchange Act of 1934.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Intellipharmaeueutics International Inc.**

(Registrant)

**/s/ Amina Odidi**

Date: October 15, 2014

Dr. Amina Odidi

*President, Chief Operating Officer and Acting Chief  
Financial Officer*

**EXHIBIT LIST**

Exhibit Description

- 99.1 Management Discussion And Analysis of Financial Condition And Results of Operations for the Three and Nine Months Ended August 31, 2014  
Condensed Unaudited Interim Consolidated Financial Statements and Notes to Condensed Unaudited Interim
- 99.2 Consolidated Financial Statements of Intellipharmaeutics International Inc. for the Three and Nine Months Ended August 31, 2014
- 99.3 News Release dated October 15, 2014 - Intellipharmaeutics Announces Third Quarter 2014 Results
- 99.4 Form 52-109F2 - Chief Executive Officer
- 99.5 Form 52-109F2 - President, Chief Operating Officer and Acting Chief Financial Officer